• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
China Heparin Industry Report, 2013-2015 - Product Image

China Heparin Industry Report, 2013-2015

  • Published: October 2013
  • Region: China
  • 84 Pages
  • Research In China

FEATURED COMPANIES

  • Changshan Biochemical
  • Dongcheng Biochemicals
  • Hepalink
  • Jiangsu Wanbang
  • Qianhong Bio-pharma
  • Tianjin Chase Sun
  • MORE

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe's total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe.

Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012. In 2012, the export volume of heparin APIs in China only registered 103.86 tons (with a year-on-year decline of 1.3%), or about 14.5 trillion units (based on 140IU/mg), addressing 46.5% of global heparin API demand in corresponding period.

Hepalink, Nanjing King-friend, Dongcheng Biochemicals and Qianhong Bio-pharma are major suppliers of heparin API around the globe. With output and sales volume of heparin API above trillion units in recent years, the four enterprises have been the largest exporters of heparin in China for consecutive years, and shared over 70% of China's total export of heparin.

Although READ MORE >

1. Overview of Heparin Industry
1.1 Definition and Classification
1.2 Industrial Chain

2. Operating Environment of Heparin Industry in China
2.1 Entry Barrier
2.1.1 Related Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Global Market Supply & Demand
2.3 Global Market Competition
2.4 Global Market Forecast

3. Development of Heparin API Industry in China
3.1 Market Status
3.2 Market Supply & Demand
3.3 Competition Pattern
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Prospect and Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Low Molecular Heparin Preparation
4.2.1 Low Molecular Heparin Calcium Preparation
4.2.2 Low Molecular Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Development Prospect and Forecast

5. Key Heparin Enterprises in China
5.1 Hepalink
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Development Prospect
5.2 Qianhong Bio-pharma
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Development Prospect
5.3 Dongcheng Biochemicals
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Clients
5.3.7 Heparin Business
5.3.8 Development Prospect
5.4 Changshan Biochemical
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Development Prospect
5.5 Tianjin Chase Sun
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Development Prospect
5.6 Nanjing King-friend
5.6.1 Profile
5.6.2 Operation and Development Prospect
5.7 Jiangsu Wanbang
5.7.1 Wanbang Biochemical
5.7.2 Operation and Development Prospect

List Of Charts:

- Application of Heparin
- Assets and Net Income of Hepalink's Holding Subsidiaries, H1 2013
- Assets, Revenue and Net Income of Qianhong Bio-pharma's Subsidiaries (Holding or Joint Stock), H1 2013
- Assets, Revenue and Profit Margin of Jiangsu Wanbang, 2012-2013"
- Capacity of Heparin Crude Products in China, 2008-2012
- Capacity of Qianhong Bio-pharma's Fund-raising Projects, 2011
- Capacity, Sales Volume and Certification of Major Heparin API Enterprises in China, 2012
- Existing and Fund-raised Heparin API and Preparation Capacities of Nanjing King-friend
- Export Average Price of Heparin and Salt in China, 2008-2013
- Export Price of Heparin and Its Salts in China, 2008-2013
- Export Volume and Export Value of Heparin and Its Salts in China, 2008-2013
- Global Demand for Heparin API, 2011-2014E
- Global Heparin API Demand and YoY Growth, 2007-2012
- Global Market Size of Heparin Preparations, 2012-2015E
- Gross Margin of Changshan Pharmaceutical by Product, 2008-2013
- Gross Margin of Chase Sun Pharmaceutical by Product, 2008-2013
- Gross Margin of Dongcheng Biochemicals by Product, 2008-2013
- Gross Margin of Hepalink by Product, 2008-2012
- Gross Margin of Major Heparin API Producers in China, 2008-2013
- Gross Margin of Qianhong Bio-pharma by Product, 2008-2013
- Hepalink's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
- Heparin Industrial Chain
- Heparin Sodium API Projects Proposed/Under Construction in China as of Jun. 2013
- Import Volume, Import Value and Unit Price of Heparin and Its Salts in China, 2008-2012
- Major Heparin Preparation Producers Worldwide
- Major Heparin Sodium Preparation Enterprises in China and Their Selling Prices, 2008-2011
- Market Share of Heparin Preparations in China by Product, 2012
- Market Size of Heparin Preparation Worldwide and YoY Growth, 2006-2012
- Market Size of Heparin Preparation in China and YoY Growth, 2012-2015
- Market Size of Heparin Preparations Around the Globe by Product, 2010-2012
- Market Size of Heparin Preparations in China and YoY Growth, 2007-2012
- Market Size of Low Molecular Weight Heparin Preparation in China, 2009-2012
- Name List and Procurement of Changshan Pharmaceutical's Top 5 Suppliers, H1 2013
- Name List and Procurement of Chase Sun Pharmaceutical's Top 5 Suppliers, 2011
- Name List and Revenue Contribution of Changshan Pharmaceutical's Top 5 Clients, 2012
- Name List and Revenue Contribution of Changshan Pharmaceutical's Top 5 Clients, H1 2013
- Name List and Revenue Contribution of Chase Sun Pharmaceutical's Top 5 Clients, 2011
- Operating Revenue of Changshan Pharmaceutical by Product, 2008-2013
- Operating Revenue of Chase Sun Pharmaceutical by Product, 2008-2013
- Operating Revenue of Dongcheng Biochemicals by Product, 2008-2013
- Operating Revenue of Dongcheng Biochemicals by Region, 2008-2013
- Output, Sales Volume and Inventory of Changshan Pharmaceutical's Heparin Sodium API and Its Preparations, 2010-2013
- Output, Sales Volume and Inventory of Chase Sun Pharmaceutical's Finished Drug Products, 2011-2012
- Output, Sales Volume and Inventory of Dongcheng Biochemicals' Heparin Sodium, 2011-2012
- Output, Sales Volume and Inventory of Hepalink's Heparin Sodium API, 2011-2012
- Performance Comparison Between Low Molecular Weight Heparin Preparation and Unfractionated Heparin Preparation
- Price of Dongcheng Biochemicals' Heparin Sodium API, 2009-2011
- Progress of Changshan Pharmaceutical's Products under Research as of Jun. 2013
- Progress of Dongcheng Biochemicals' Projects under Research by the End of 2012
- Progress of Qianhong Bio-pharma's Projects Proposed/Under Construction as of Jun. 2013
- Qianhong Bio-pharma's Procurement from Top 5 Suppliers and Revenue from Top 5 Clients, 2009-2013
- R&D Costs and % of Total Revenue of Changshan Pharmaceutical, 2009-2013
- R&D Costs and % of Total Revenue of Chase Sun Pharmaceutical, 2009-2012
- R&D Costs and % of Total Revenue of Dongcheng Biochemicals, 2010-2012
- R&D Costs and % of Total Revenue of Hepalink, 2009-2013
- R&D Costs and % of Total Revenue of Qianhong Bio-pharma, 2009-2013
- Regional Distribution of Heparin Preparations Worldwide, 2012
- Revenue Contribution of Top 5 Clients of Dongcheng Biochemicals' Heparin Sodium API Business, 2009-2011
- Revenue and Gross Margin of Chase Sun Pharmaceutical's Heparin Business, 2008-2013
- Revenue and Gross Margin of Dongcheng Biochemicals' Heparin Sodium API, 2008-2013
- Revenue and Gross Margin of Qianhong Bio-pharma's Heparin Business, 2008-2013
- Revenue and Net Income of Changshan Pharmaceutical, 2012-2015E
- Revenue and Net Income of Chase Sun Pharmaceutical, 2012-2015E
- Revenue and Operating Income of Hepalink, 2012-2015E
- Revenue and Operating Income of Qianhong Bio-pharma, 2011-2014
- Revenue and Profit of Changshan Pharmaceutical, 2008-2013
- Revenue and Profit of Chase Sun Pharmaceutical, 2008-2013
- Revenue and Profit of Dongcheng Biochemicals, 2008-2013
- Revenue and Profit of Dongcheng Biochemicals, 2012-2015E
- Revenue and Profit of Hepalink, 2008-2013
- Revenue and Profit of Qianhong Bio-pharma, 2008-2012
- Revenue of Changshan Pharmaceutical by Region, 2008-2013
- Revenue of Chase Sun Pharmaceutical by Region, 2008-2013
- Revenue of Hepalink by Product, 2008-2013
- Revenue of Hepalink by Region, 2008-2013
- Revenue of Qianhong Bio-pharma by Product, 2008-2013
- Revenue of Qianhong Bio-pharma by Region, 2008-2013
- Sales of Major Heparin Preparation Brands Globally, 2010-2012
- Standard Requirements of Heparin Sodium API and Heparin in China
- Top 10 Export Destinations of China's Heparin and Its Salts by Export Value, 2012-2013
- Top 10 Export Enterprises of Heparin and Its Salts in China by Export Value, 2012

- Changshan Biochemical
- Dongcheng Biochemicals
- Hepalink
- Jiangsu Wanbang
- Qianhong Bio-pharma
- Tianjin Chase Sun
- Wanbang Biochemical

Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos